CKPT Stock Price, Checkpoint Therapeutics Quote, Chart

Market Summary

USD1.68-0.04

Market Closed

-2.33%

CKPT Stock Price

View Fullscreen

CKPT RSI Chart

CKPT Valuation

Market Cap

46.5M

Price/Earnings (Trailing)

-0.9

Price/Sales (Trailing)

451.58

Price/Free Cashflow

-0.98

CKPT Price/Sales (Trailing)

CKPT Profitability

Return on Equity

397.39%

Return on Assets

-964.06%

Free Cashflow Yield

-102.32%

CKPT Fundamentals

CKPT Revenue

Revenue (TTM)

103.0K

Rev. Growth (Yr)

-91.89%

Rev. Growth (Qtr)

-80.65%

CKPT Earnings

Earnings (TTM)

-51.8M

Earnings Growth (Yr)

9.01%

Earnings Growth (Qtr)

-234.17%

Breaking Down CKPT Revenue

Last 7 days

-5.5%

Last 30 days

-10.4%

Last 90 days

-8.5%

Trailing 12 Months

-34.1%

How does CKPT drawdown profile look like?

CKPT Financial Health

Current Ratio

0.29

CKPT Investor Care

Shares Dilution (1Y)

182.08%

Diluted EPS (TTM)

-3.25

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	175.0K	188.0K	171.0K	103.0K
2022	252.0K	115.0K	134.0K	192.0K
2021	165.0K	278.0K	279.0K	268.0K
2020	2.3M	1.3M	1.1M	1.1M
2019	3.5M	4.4M	4.7M	1.7M
2018	1.4M	1.2M	807.0K	3.5M
2017	3.0M	2.1M	1.9M	1.7M
2016	1.1M	1.6M	2.1M	2.6M
2015	0	0	0	590.0K

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Checkpoint Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 20, 2024	fortress biotech, inc.	acquired	-	-	193,905	-
Feb 28, 2024	oliviero james f iii	sold	-12,141	2.06	-5,894	ceo, president and director
Feb 28, 2024	oliviero james f iii	gifted	-	-	-9,056	ceo, president and director
Feb 28, 2024	gray william garrett	sold	-4,212	2.07	-2,035	chief financial officer
Feb 01, 2024	gray william garrett	sold	-8,024	1.95	-4,115	chief financial officer
Feb 01, 2024	oliviero james f iii	gifted	-	-	-12,950	ceo, president and director
Feb 01, 2024	oliviero james f iii	sold	-23,919	2.01	-11,900	ceo, president and director
Dec 29, 2023	fortress biotech, inc.	acquired	-	-	158,134	-
Sep 25, 2023	fortress biotech, inc.	acquired	-	-	80,906	-
Aug 16, 2023	oliviero james f iii	gifted	-	-	-12,510	ceo, president and director

Which funds bought or sold CKPT recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 15, 2024	WEALTH ENHANCEMENT ADVISORY SERVICES, LLC	reduced	-41.18	-92,150	102,500	-%
Apr 10, 2024	PARK AVENUE SECURITIES LLC	reduced	-0.03	-14,000	123,000	-%
Mar 15, 2024	B. Riley Wealth Advisors, Inc.	added	232	290,517	374,072	0.01%
Mar 12, 2024	PVG ASSET MANAGEMENT CORP	added	3.92	75,459	264,201	1.28%
Mar 11, 2024	VANGUARD GROUP INC	added	13.61	435,143	1,255,620	-%
Mar 01, 2024	ARK & TLK INVESTMENTS, LLC	new	-	22,900	22,900	0.01%
Feb 15, 2024	JANE STREET GROUP, LLC	new	-	92,839	92,839	-%
Feb 14, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-44.14	-8,977	27,299	-%
Feb 14, 2024	IRONWOOD INVESTMENT MANAGEMENT LLC	reduced	-8.73	4,992	26,754	0.01%
Feb 14, 2024	Royal Bank of Canada	reduced	-0.9	35,000	139,000	-%

Are Funds Buying or Selling CKPT?

Are funds buying CKPT calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own CKPT

No. of Funds

Unveiling Checkpoint Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 22, 2024	fortress biotech, inc.	7.5%	2,796,278	SC 13D/A
Feb 14, 2024	armistice capital, llc	9.99%	2,715,635	SC 13G/A
Sep 26, 2023	fortress biotech, inc.	11.3%	2,444,239	SC 13D/A
Jul 06, 2023	fortress biotech, inc.	13.6%	2,363,333	SC 13D/A
Apr 19, 2023	fortress biotech, inc.	17.5%	2,281,927	SC 13D/A
Feb 14, 2023	armistice capital, llc	9.99%	987,211	SC 13G
Jan 13, 2023	fortress biotech, inc.	19.3%	2,203,713	SC 13D/A
May 07, 2021	blackrock inc.	4.8%	3,487,614	SC 13G/A
Feb 16, 2021	cvi investments, inc.	-	636,964	SC 13G/A
Feb 02, 2021	blackrock inc.	5.3%	3,240,599	SC 13G

Recent SEC filings of Checkpoint Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
Apr 05, 2024	EFFECT	EFFECT
Apr 02, 2024	DEF 14A	DEF 14A
Apr 02, 2024	DEFA14A	DEFA14A
Mar 29, 2024	S-3	S-3
Mar 22, 2024	10-K	Annual Report
Mar 22, 2024	4	Insider Trading
Mar 22, 2024	8-K	Current Report
Mar 22, 2024	PRE 14A	PRE 14A
Mar 22, 2024	SC 13D/A	13D - Major Acquisition
Mar 19, 2024	3	Insider Trading

Peers (Alternatives to Checkpoint Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.7B	6.8B	0.01%	-33.89%	-8.41	5.79	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.5B	1.8B	-1.06%	-27.57%	-42.01	10.12	76.23%	61.08%
BMRN	17.2B	2.4B	9.12%	-7.56%	102.31	7.09	15.42%	18.43%
INCY	11.9B	3.7B	-8.48%	-28.30%	20	3.23	8.87%	75.42%
MID-CAP
APLS	6.2B	396.6M	-9.27%	-36.41%	-11.74	15.65	425.83%	18.94%
BBIO	4.4B	-	-6.46%	74.90%	-6.81	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-9.62%	-0.34%	-13.62	12.04	440.80%	-27.84%
ARWR	2.9B	240.7M	-15.06%	-21.14%	-9.88	12.18	-1.03%	-92.09%
ACAD	2.8B	726.4M	-8.60%	-6.11%	-45.95	3.88	40.45%	71.62%
SMALL-CAP
CPRX	1.8B	398.2M	-4.17%	-12.95%	25.63	4.6	85.90%	-14.05%
NVAX	557.0M	983.7M	-22.12%	-55.02%	-1.02	0.57	-50.36%	17.16%
CRBP	432.8M	881.7K	-2.13%	345.78%	-9.7	466.16	-77.61%	-5.33%
INO	225.3M	4.9M	2.33%	7.75%	-1.67	46.29	-54.97%	51.72%
IBIO	6.8M	2.1M	82.86%	81.13%	-0.25	2.14	-13.45%	66.37%

Checkpoint Therapeutics Inc News

Latest updates

Checkpoint Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	-80.6%	6.00	31.00	31.00	35.00	74.00	48.00	18.00	52.00	16.00	29.00	155	68.00	27.00	28.00	42.00	972	25.00	280	1,051	352	3,031
Operating Expenses	31.6%	10,175	7,732	16,226	18,118	16,718	10,712	14,182	16,913	29,786	11,307	9,312	6,586	10,269	4,972	4,716	4,313	8,882	5,514	5,878	6,284	14,923
S&GA Expenses	-16.1%	1,876	2,236	2,281	2,292	2,482	1,846	2,129	2,243	2,128	1,923	2,114	2,373	2,124	2,429	1,687	1,678	2,152	1,620	1,758	1,703	1,502
R&D Expenses	51.0%	8,299	5,496	13,945	15,826	14,236	8,866	12,053	14,670	27,658	9,384	7,198	4,213	8,145	2,543	3,029	2,635	6,730	3,894	4,120	4,581	13,421
Net Income	-234.2%	-19,128	-5,724	-16,521	-10,474	-21,022	-10,612	-14,142	-16,848	-29,756	-11,265	-9,144	-6,505	-10,225	-4,930	-4,645	-3,281	-8,826	-5,206	-4,792	-5,890	-11,619
Net Income Margin	-60.2%	-503.37*	-314.27*	-311.86*	-321.43*	-326.17*	-532.52*	-626.18*	-265.92*	-211.46*	-133.11*	-110.81*	-159.42*	-21.59*	-20.32*	-16.65*	-9.50*	-14.47*	-5.84*	-7.13*	-9.53*	-10.37*
Free Cashflow	53.7%	-6,833	-14,750	-11,976	-14,031	-15,300	-11,417	-11,231	-19,606	-9,478	-6,463	-5,708	-4,657	-4,934	-4,916	-2,161	-4,540	-4,729	-3,486	-4,955	-8,203	-7,605

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	142.5%	5.00	2.00	8.00	6.00	13.00	22.00	32.00	43.00	56.00	61.00	66.00	61.00	43.00	43.00	23.00	23.00	27.00	14.00	15.00	15.00	25.00
Current Assets	142.5%	5.00	2.00	8.00	6.00	13.00	22.00	32.00	43.00	56.00	61.00	66.00	61.00	43.00	43.00	23.00	23.00	27.00	14.00	15.00	15.00	25.00
Cash Equivalents	178.1%	5.00	2.00	7.00	5.00	12.00	20.00	31.00	41.00	55.00	60.00	65.00	60.00	41.00	42.00	22.00	21.00	26.00	13.00	13.00	14.00	22.00
Liabilities	-13.3%	18.00	21.00	32.00	28.00	33.00	23.00	25.00	23.00	26.00	13.00	9.00	7.00	7.00	6.00	8.00	7.00	8.00	8.00	8.00	8.00	13.00
Current Liabilities	-13.3%	18.00	21.00	32.00	28.00	33.00	23.00	25.00	23.00	26.00	13.00	9.00	7.00	7.00	6.00	8.00	7.00	8.00	8.00	8.00	8.00	13.00
Shareholder's Equity	-Infinity%	-13.05	-	-	-	-19.48	-	7.00	20.00	30.00	48.00	57.00	54.00	35.00	36.00	15.00	16.00	19.00	6.00	7.00	7.00	12.00
Retained Earnings	-6.5%	-314	-295	-289	-273	-262	-241	-230	-216	-199	-170	-158	-149	-143	-133	-128	-123	-120	-111	-106	-101	-95.40
Additional Paid-In Capital	7.9%	298	276	266	251	241	240	238	237	223	218	216	204	174	169	143	137	136	118	113	108	105
Shares Outstanding	24.6%	27.00	22.00	17.00	13.00	10.00	9.00	9.00	9.00	8.00	8.00	7.00	7.00	6.00	6.00	5.00	5.00	5.00	3.00	3.00	3.00	3.00
Float	-	-	-	-	-	-	-	71.00	-	-	-	185	-	-	-	81.00	-	-	-	69.00	-	-

Cashflow (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	53.7%	-6,833	-14,750	-11,976	-14,031	-15,300	-11,417	-11,231	-19,606	-9,478	-6,463	-5,708	-4,657	-4,934	-4,916	-2,161	-4,540	-4,729	-3,486	-4,955	-8,203	-7,605
Share Based Compensation	-2.5%	672	689	567	969	639	781	729	775	818	779	766	774	685	725	731	639	677	833	813	798	-342
Cashflow From Investing	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cashflow From Financing	9.8%	9,989	9,101	14,551	6,809	6,890	1,008	642	6,347	4,010	1,542	10,799	23,918	3,677	25,021	2,604	-56.00	17,746	3,341	4,013	355	-

CKPT Income Statement

2023-12-31

STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	12 Months Ended
STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
STATEMENTS OF OPERATIONS
Revenue - related party	$ 103	$ 192
Revenue, Related Party, Type [Extensible Enumeration]	us-gaap:RelatedPartyMember	us-gaap:RelatedPartyMember
Operating expenses:
Research and development	$ 43,566	$ 49,825
General and administrative	8,685	8,700
Total operating expenses	52,251	58,525
Loss from operations	(52,148)	(58,333)
Other income (loss):
Interest income	84	160
Gain (loss) on common stock warrant liabilities	217	(4,451)
Total other income (loss)	301	(4,291)
Net Loss	$ (51,847)	$ (62,624)
Loss per Share:
Basic net loss per common share outstanding	$ (3.17)	$ (7.09)
Diluted net loss per common share outstanding	$ (3.17)	$ (7.09)
Basic weighted average number of common shares outstanding	18,742,494	8,835,521
Diluted weighted average number of common shares outstanding	18,742,494	8,835,521

CKPT Balance Sheet

2023-12-31

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current Assets:
Cash and cash equivalents	$ 4,928	$ 12,068
Prepaid expenses and other current assets	450	1,149
Other receivables - related party		73
Total current assets	5,378	13,290
Total Assets	5,378	13,290
Current Liabilities:
Accounts payable and accrued expenses	15,485	20,297
Accounts payable and accrued expenses - related party	2,815	1,306
Common stock warrant liabilities	125	11,170
Total current liabilities	18,425	32,773
Total Liabilities	18,425	32,773
Commitments and Contingencies (note 5)
Stockholders' Equity (Deficit)
Common stock issuable, 1,492,915 and 368,907 shares as of December 31, 2023 and December 31, 2022, respectively	3,419	1,885
Additional paid-in capital	297,864	241,117
Accumulated deficit	(314,333)	(262,486)
Total Stockholders' Equity (Deficit)	(13,047)	(19,483)
Total Liabilities and Stockholders' Equity (Deficit)	5,378	13,290
Common No Class
Stockholders' Equity (Deficit)
Common Stock Value	$ 3	$ 1

About Checkpoint Therapeutics Inc

Checkpoint Therapeutics, Inc., a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's lead antibody product candidate is Cosibelimab, a fully-human monoclonal antibody of IgG1 subtype that directly binds to programmed death ligand-1 (PD-L1) and blocks the PD-L1 interaction with the programmed death receptor-1 and B7.1 receptors; and CK-302, a human agonistic antibody that is designed to bind to and trigger signaling in GITR expressing cells. It is also developing Olafertinib, a third-generation epidermal growth factor receptor (EGFR) inhibitor, as a treatment for patients with EGFR mutation-positive non-small cell lung cancer; CK-103, a selective and potent small molecule inhibitor of bromodomain and extra-terminal bromodomains; and anti-carbonic anhydrase IX (CAIX) antibody, a fully human preclinical antibody to recognize CAIX expressing cells and kill them via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. The company has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was incorporated in 2014 and is based in Waltham, Massachusetts. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

CEO	Mr. James F. Oliviero III, C.F.A., CFA
WEBSITE	checkpointtx.com
INDUSTRY	Biotechnology
EMPLOYEES	24

Checkpoint Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for Checkpoint Therapeutics Inc? What does CKPT stand for in stocks?

CKPT is the stock ticker symbol of Checkpoint Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Checkpoint Therapeutics Inc (CKPT)?

As of Mon Apr 15 2024, market cap of Checkpoint Therapeutics Inc is 46.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CKPT stock?

You can check CKPT's fair value in chart for subscribers.

What is the fair value of CKPT stock?

You can check CKPT's fair value in chart for subscribers. The fair value of Checkpoint Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Checkpoint Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CKPT so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Checkpoint Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether CKPT is over valued or under valued. Whether Checkpoint Therapeutics Inc is cheap or expensive depends on the assumptions which impact Checkpoint Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CKPT.

What is Checkpoint Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 15 2024, CKPT's PE ratio (Price to Earnings) is -0.9 and Price to Sales (PS) ratio is 451.58. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CKPT PE ratio will change depending on the future growth rate expectations of investors.